Catalent, facing pressure from Elliott, had other activists in stock
By Svea Herbst-Bayliss NEW YORK (Reuters) – Contract drugmaker Catalent, which is being pushed to make changes to its board by Elliott Investment Management, had at least two other activist investors in its stock at the end of the second quarter, according to new regulatory filings. Keith Meister’s Corvex Management and Scott Ferguson’s Sachem Head…
